论文部分内容阅读
目的通过比较GP(吉西他滨+顺铂)方案与氨磷汀联合GP方案的不良反应,为氨磷汀的合理应用及药学监护提供理论参考。方法收集我院肿瘤科2011年7月至2013年12月应用GP方案的患者42例,氨磷汀联合GP方案的患者37例,分别记录2组患者每周期化疗后的不良反应,并进行对比分析。结果与GP方案组比较,氨磷汀联合GP方案组的恶心呕吐发生率明显升高(P<0.01),并出现严重的消化道反应(P<0.01),头晕和低血压发生率增加(P<0.05)。结论联合氨磷汀化疗易出现严重的恶心呕吐及低血压等不良反应。临床除常规监测血常规和肝肾功能外,化疗期间应积极预防消化道反应,每天监测血压,及时对症支持治疗,以保证患者用药安全。
Objective To compare the adverse effects of GP (gemcitabine + cisplatin) regimen with amifostine in combination with GP regimen, and to provide a theoretical reference for rational use of amifostine and pharmacy care. Methods Totally 42 patients with GP regimen from July 2011 to December 2013 in our department were enrolled. 37 patients were treated with amifostine combined with GP regimen. The adverse reactions of each group after chemotherapy were recorded and compared analysis. Results Compared with the GP regimen group, the incidence of nausea and vomiting was significantly increased in the amifostine plus GP group (P <0.01), with severe digestive reaction (P <0.01) and increased incidence of dizziness and hypotension (P <0.05). Conclusions The combination of amifostine chemotherapy is prone to serious nausea and vomiting and hypotension and other adverse reactions. In addition to clinical routine monitoring of blood and liver and kidney function, the chemotherapy should be active during the prevention of gastrointestinal reactions, blood pressure monitoring every day, timely symptomatic and supportive care to ensure that patients medication safety.